INAB Stock Risk & Deep Value Analysis
IN8bio Inc
DVR Score
out of 10
What You Need to Know About INAB Stock
We analyzed IN8bio Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran INAB through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
INAB Risk Analysis & Red Flags
What Could Go Wrong
The company is a pre-revenue biotech heavily reliant on binary clinical outcomes. If their lead assets, INB-200/400, fail to show compelling efficacy or safety in ongoing trials, or if they cannot secure significant future funding without severe dilution, the stock could face catastrophic losses, potentially leading to delisting or bankruptcy.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Auditor raised going concern doubt in the 2025 annual 10-K filing due to rapid cash burn.
- ⚠
Pre-revenue status with significant net losses ($20.66M in 2025).
- ⚠
Heavy reliance on future dilutive capital raises for operational continuity.
- ⚠
Low market cap makes it susceptible to extreme volatility.
Upcoming Risk Events
- 📅
Negative or inconclusive clinical trial results for INB-200/400 or INB-100
- 📅
Failure to secure additional financing leading to further dilution or operational slowdowns
- 📅
Competition from other cellular therapy developers achieving faster clinical progress
When to Reconsider
- 🚪
Failure to achieve planned clinical trial milestones within specified timelines (e.g., no meaningful data update on INB-200/400 in next 6-9 months).
- 🚪
Announcement of a highly dilutive financing round (e.g., greater than 25-30% dilution at current market prices).
- 🚪
Competitors achieving significantly superior clinical results in similar indications.
Unlock INAB Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
IN8bio is a highly speculative, high-risk, high-reward investment banking on the success of its innovative allogeneic gamma-delta T-cell therapies for difficult-to-treat cancers like glioblastoma and AML. With a substantial TAM and promising early clinical data, successful trial progression and strategic partnerships could unlock exponential growth. However, significant financial risks and reliance on binary clinical outcomes make it suitable only for investors with a high-risk tolerance and long-term outlook.
Is INAB Stock Undervalued?
Unlock the full AI analysis for INAB
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
INAB Price Targets & Strategy
12-Month Target
$3.50
Bull Case
$7.00
Bear Case
$0.50
Valuation Basis
Based on a successful Phase 1/2 clinical update for INB-200/400 and a 0.7x P/B on future projected book value (post-financing), reflecting early-stage biotech speculative premium.
Entry Strategy
Given the high-risk nature, dollar-cost average into any dips near historical support levels. Monitor for positive clinical data readouts as potential entry points after initial market reaction stabilizes.
Exit Strategy
Take profit on significant positive clinical milestones (e.g., successful Phase 2 data, accelerated approval pathway). Stop loss at $0.80 if cash burn accelerates without new funding or clinical setbacks.
Portfolio Allocation
2% for aggressive risk tolerance.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is INAB Financially Healthy?
Profitability
Return on Equity
-111.30%
EPS
$-4.78
Balance Sheet
Current Ratio
8.82
Quick Ratio
8.65
Debt/Equity
0.01
Cash Flow
EBITDA
-$19.02M
Other
Beta (Volatility)
0.08
Does INAB Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is currently nascent but expanding as clinical trials progress and IP is strengthened. Success in Phase 1/2 trials will validate the platform, making it harder for new entrants to replicate. However, it is vulnerable to competing technologies or larger players entering the space.
Moat Erosion Risks
- •Failure of clinical trials leading to loss of competitive advantage to alternative therapies.
- •Expiry or invalidation of key patents.
- •Emergence of superior or more cost-effective treatment modalities.
INAB Competitive Moat Analysis
Sign up to see competitive advantages
INAB Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. Retail interest likely speculative given low price and high-risk profile, often fueled by clinical news.
Institutional Sentiment
Neutral. No recent analyst coverage, upgrades, or downgrades reported. Institutional ownership is unknown but likely low given small market cap.
Insider Activity (Form 4)
Minor inducement grants of options for 11,800 shares to two new employees on April 1, 2026. No significant buy/sell activity from executives (CEO/CFO) or directors reported in the last 90 days.
Options Flow
Normal options activity. Given the small market cap and high-risk profile, significant institutional options positioning is less common.
Earnings Intelligence
Next Earnings
2026-05-06 (Q1 2026 earnings announced)
Surprise Probability
Medium. As a pre-revenue biotech, focus is on cash burn and clinical updates rather than EPS. A smaller-than-expected loss or positive clinical update could surprise.
Historical Earnings Pattern
Likely volatile, with stock movement largely tied to clinical updates and cash runway rather than traditional financial metrics. Strong positive clinical news would likely lead to significant rallies, while negative news or funding concerns would cause sharp declines.
Key Metrics to Watch
Competitive Position
Top Competitor
Precise 'best competitor' is difficult without more context, but companies developing other novel cellular therapies for cancer such as CAR-T or other adoptive T-cell therapies (e.g., ALLL, ARWR, MIRA) would be in a similar high-risk, high-reward category. IN8bio's unique focus on allogeneic gamma-delta T-cells differentiates it.
Market Share Trend
Not applicable as the company is pre-revenue and in clinical trials. It aims to create new market share in specific oncology niches.
Valuation vs Peers
Trading at a low P/B of 0.5x compared to sector median of 2.6x, reflecting significant financial risk and pre-revenue status. Negative TTM P/E and PEG are typical for early-stage biotechs.
Competitive Advantages
- •Proprietary allogeneic gamma-delta T-cell platform (INB-100, INB-200/400, INB-600)
- •Early clinical data suggesting survival improvements in glioblastoma vs. standard care
- •Potential for off-the-shelf allogeneic therapies (reducing cost/complexity vs. autologous CAR-T)
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive INAB Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Announcement (May 6, 2026)
- •Annual Meeting of Stockholders (May 7, 2026)
- •Further updates on INB-200/400 (glioblastoma) Phase 1/2 clinical data
Medium-Term (6-18 months)
- •Progression of INB-200/400 into later-stage clinical trials
- •Strategic partnership or licensing deal for gamma-delta T-cell platform
- •IND filing for INB-600 engager (preclinical program)
Long-Term (18+ months)
- •Potential market leadership in allogeneic gamma-delta T-cell therapies for solid tumors
- •Disruption of existing cancer treatment paradigms for GBM and AML
- •Platform expansion into additional high-unmet-need indications
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for INAB?
- ✓
Positive clinical trial readouts for INB-200/400 (especially Phase 2 data).
- ✓
New strategic partnerships or significant non-dilutive funding announcements.
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How IN8bio Inc Makes Money
IN8bio is a clinical-stage biotechnology company focused on developing a novel class of cellular therapies, specifically allogeneic gamma-delta T-cells, to treat various cancers. They do not currently generate revenue from product sales. Instead, their business model involves incurring significant research and development expenses to advance their drug candidates through preclinical and clinical trials. The long-term goal is to bring these therapies to market, generating revenue through licensing agreements with larger pharmaceutical companies or by commercializing the therapies themselves if approved. Success hinges on positive clinical trial outcomes and regulatory approvals.
Read Full Business Model BreakdownFAQ
What is the DVR Score for IN8bio Inc (INAB)?
As of April 16, 2026, IN8bio Inc has a DVR Score of 6.5 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of IN8bio Inc?
IN8bio Inc's market capitalization is approximately $13.6M..
What is the risk level for INAB stock?
Our analysis rates IN8bio Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the INAB DVR analysis updated?
Our AI-powered analysis of IN8bio Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 16, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for INAB (IN8bio Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.